Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions

International Journal of Oncology

Volumn 32, Issue 6, 2008, Pages 1263-1274

  Nishida, Michio ^a   Teshigawara, Keisuke ^a   Niwa, Otsura ^a   Usuda, Sadakazu ^b   Nakamura, Tetsuo ^b   Ralph, Peter ^c   Newman, Roland ^d   Padlan, Eduardo A ^e  

^a KYOTO UNIVERSITY   (Japan)

^b BioMedics Japan Inc   (Japan)

^c Marin Biologic Laboratories Inc   (United States)

^d RANA Consulting   (United States)

^e University of the Philippines Diliman   (Philippines)

Author keywords

Anti CD20 monoclonal antibody; Antibody dependent cellular cytotoxicity; Apoptosis; Binding epitope; Complement dependent cytotoxicity; Germline gene family; Humanized

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG; CASPASE; CD20 ANTIGEN; COMPLEMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

AMINO ACID SUBSTITUTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CROSS LINKING; GENE REARRANGEMENT; GERM LINE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR CELL; AMINO ACID SEQUENCE; CYTOTOXICITY; ENZYME ACTIVATION; GENETICS; IMMUNOLOGY; LEUKEMIA; LYMPHOMA; METABOLISM; MOLECULAR GENETICS; NECROSIS; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; APOPTOSIS; CASPASES; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ACTIVATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; LEUKEMIA; LYMPHOMA; MOLECULAR SEQUENCE DATA; NECROSIS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 48149111997     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_32_6_1263     Document Type: Article

References (38)

1. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A and Introna M: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement- mediated cell lysis. Blood 95: 3900-3908, 2000.
2. Semac I, Palomba C, Kulangara K, Klages N, van Echten-Deckert G, Borisch B and Hoessli DC: Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 15: 534-540, 2003.
3. Deans JP, Haidong LI and Polyak MJ: CD20-mediated apoptosis signaling through lipid rafts. Immunology 107: 176-182, 2002.
4. Jazirehi AR and Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24: 2121-2143, 2005.
5. Jazirehi AR, Huerta-Yepez S, Cheng G and Bonavida B: Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65: 264-276, 2005.
6. Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, Clark EA and Ledbetter JA: Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 151: 4494-4504, 1993.
7. Polyak MJ and Deans JP: Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the free specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99: 3256-3262, 2002.
8. Polyak MJ, Tailor SH and Deans JP: Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 161: 3242-3248, 1998.
9. Perosa F, Favoino E, Caragnano MA and Dammacco F: Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phospho-diesterase 3b precursor. Blood 107: 1070-1077, 2006.
10. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ and van de Winkel JG: The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177: 362-371, 20O6.
11. Glennie MJ, French RR, Cragg MS and Taylor RP: Mechanism of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-3837, 2007.
12. Golay J, Gramigna R, Facchinetti V, Capello D and Introna M: Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 119: 923-929, 2002.
13. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG and Glennie MJ: Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800, 2004.
14. Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K and Niwa O: Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol 31: 29-40, 2007.
15. Urlaub G, Mitchell PJ, Kas E, Chasin LA, Funanage VL, Myoda TT and Hamlin J: Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat Cell Mol Genet 12: 555-566, 1986.
16. Teeling J, Ruuls S, Glennie M, von de Winkel JDG, Parren P, Petersen J, Baadsgaard O and Huang H: Human monoclonal antibody against CD20. United State Patent Publication No. US 2004/0167319 A1, 2004.
17. Johnston CM, Wood AL, Bolland DJ and Corcoran AE: Complete sequence assembly and characterization of the C57BL/6 mouse Ig heavy chain V region. J Immunol 176: 4221-4234, 2006,
18. Thiebe R, Schäble KF, Bensch A, Brensing-Küppers J, Heim V, Kirschbaum T, Mitlöhner H, Ohnrich M, Pourrajabi S, Röschenahaler F, Schwendinger J, Wichelhaus D, Zocher I and Zachau HG: The variable genes and gene families of the mouse immunoglobulin kappa locus. Eur Immunol 29: 2072-2081, 1999.
19. Brekke KM and Garrard WT: Assembly and analysis of the mouse immunoglobulin kappa gene sequence. Immunogenetics 56: 490-505, 2004.
20. Ohtani K, Suzuki Y, Eda S, Kawai T, Kase T, Keshi H, Sakai Y, Yamamoto S, Sakamoto T and Wakamiya N: High-level and effective production of human mannan-binding lectin (MBL) in Chinese hamster ovary (CHO) cells. J Immunol Methods 222: 135-144, 1999.
21. Padlan EA: A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 28: 489-498, 1991.
22. Padlan EA, Abergel C and Tipper JP: Identification of specificity-determining residues in antibodies. FASEB J 9: 133-139, 1995.
23. Wu TT and Kabat EA: Possible use of similar framework region amino acid sequences between human and mouse immunoglobulin for humanizing mouse antibodies. Mol Immunol 29: 1141-1146, 1992.
24. Gazzano-Santoro H, Ralph P, Ryskamp TC, Chen AB and Mukku VR: A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods 202: 163-171, 1997.
25. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng G and Mulkerrin MG: Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164: 4178-4184, 2000.
26. Rose AL, Smith BE and Maloney DG: Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 100: 1765-1773, 2002.
27. GraphPad Software, Inc: Fitting Models to Biological Data Using Linear and Nonlinear Regression, 2003.
28. Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ and Cragg MS: CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 63: 5480-5489, 2003.
29. Stanglmaier M, Reis S and Hallek M: Rituximab and alemtuzumab induce a non-classic caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 83: 634-645, 2004.
30. Daniels I, Abulayha AM, Thomson BJ and Haynes AP: Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 11: 1013-1023, 2006.
31. Rock EP, Sibbald PR, Davis MM and Chien YH: CDR3 length in antigen-specific immune receptors. J Exp Med 179: 323-328, 1994.
32. Seidl KJ, MacKenzie JD, Wang D, Kantor AB, Kabat EA, Herzenberg LA and Herzenberg LA: Frequent occurrence of identical heavy and light chain Ig rearrangement. Int Immunol 9: 689-702, 1997.
33. Arnold LW, Spencer DH, Clarke SH and Haughton G: Mechanisms that limit the diversity of antibody: three sequentially acting mechanisms that favor the spontaneous production of germline encoded anti-phophatidyl choline. Int Immunol 5: 1365-1373, 1993.
34. Li Y, Spellerberg MB, Stevenson FK, Capra JD and Potter KN: The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3. J Mol Biol 256: 577-589, 1996.
35. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, French RR and Glennie MJ: Complement mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101: 1045-1052, 2003.
36. Johnson TA, Rassenti LZ and Kipps TJ: Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 158: 235-246, 1997.
37. Cragg MS and Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103: 2738-2743, 2004.
38. 1)2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 51: 15-24, 2002.